These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
543 related articles for article (PubMed ID: 8497119)
1. [In vitro antimycobacterial activity of clarithromycin and its therapeutic efficacy against Mycobacterium intracellulare infection induced in mice]. Tomioka H; Sato K; Saito H Kekkaku; 1993 Apr; 68(4):293-9. PubMed ID: 8497119 [TBL] [Abstract][Full Text] [Related]
2. [Studies on therapeutic efficacy of a new anti-tuberculous drug, benzoxazinorifamycin, against murine experimental mycobacterial infections: attempt at various regimens and protocols]. Tomioka H; Saito H Kekkaku; 1994 Nov; 69(11):703-10. PubMed ID: 7837724 [TBL] [Abstract][Full Text] [Related]
3. [Antimycobacterial activities of a new quinolone, sparfloxacin]. Tomioka H; Sato K; Saito H Kekkaku; 1991 Oct; 66(10):643-9. PubMed ID: 1660089 [TBL] [Abstract][Full Text] [Related]
4. [In vivo activities of benzoxazinorifamycin KRM-1648, clarithromycin, and levofloxacin, or combination of KRM-1648 with diclofenac sodium against Mycobacterium avium infection induced in mice]. Akaki T; Sato K; Shimizu T; Tomioka H; Kawahara S Kekkaku; 1997 Aug; 72(8):491-7. PubMed ID: 9293712 [TBL] [Abstract][Full Text] [Related]
5. Activity of capuramycin analogues against Mycobacterium tuberculosis, Mycobacterium avium and Mycobacterium intracellulare in vitro and in vivo. Koga T; Fukuoka T; Doi N; Harasaki T; Inoue H; Hotoda H; Kakuta M; Muramatsu Y; Yamamura N; Hoshi M; Hirota T J Antimicrob Chemother; 2004 Oct; 54(4):755-60. PubMed ID: 15347635 [TBL] [Abstract][Full Text] [Related]
6. [Evaluation of a newly developed broth microdilution test method to determine minimum inhibitory concentrations (MICs) of antimicrobial agents for mycobacteria]. Yamane N; Nakasone I; Saitoh H; Kaneda M; Shimojima M; Yamashita K; Toyoda K; Okazawa Y Rinsho Byori; 1998 Jul; 46(7):719-27. PubMed ID: 9721542 [TBL] [Abstract][Full Text] [Related]
7. [Therapeutic efficacy of a benzoxazinorifamycin, KRM-1648, in Mycobacterium intracellulare infection induced in mice]. Saito H; Tomioka H; Sato K; Hidaka T Kekkaku; 1994 Feb; 69(2):59-63. PubMed ID: 8126989 [TBL] [Abstract][Full Text] [Related]
8. [Therapeutic efficacy of a benzoxazinorifamycin, KRM-1648, administered at the different periods of infection in Mycobacterium intracellulare--infected mice]. Tomioka H; Sato K; Saito H; Hidaka T Kekkaku; 1993 Oct; 68(10):631-5. PubMed ID: 8255070 [TBL] [Abstract][Full Text] [Related]
10. [Antimicrobial activity of new quinolones against Mycobacterium avium and Mycobacterium intracellulare determined by the dilution methods using 7H11 agar and Ogawa egg media]. Tomioka H; Sato K; Saito H Kekkaku; 1993 May; 68(5):367-70. PubMed ID: 8331881 [TBL] [Abstract][Full Text] [Related]
11. [Antimycobacterial susceptibility against nontuberculous mycobacteria using brothmic NTM]. Kawata N; Kawahara S; Tada A; Takigawa N; Shibayama T; Soda R; Takahashi K Kekkaku; 2006 Apr; 81(4):329-35. PubMed ID: 16715941 [TBL] [Abstract][Full Text] [Related]
12. [In vitro susceptibilities of Mycobacterium avium and Mycobacterium intracellulare to new macrolides, new quinolones, and antituberculous drugs on Dubos agar medium]. Ogawa K; Miwa T; Sasamoto M; Sasaki T; Tsuda M; Honda K; Furui H; Torii K; Takagi K Kekkaku; 1992 Nov; 67(11):735-8. PubMed ID: 1487866 [TBL] [Abstract][Full Text] [Related]
13. [Therapeutic efficacy of macrolide in pulmonary nontuberculous mycobacteriosis]. Tomono K Kekkaku; 1994 Nov; 69(11):725-32. PubMed ID: 7837727 [TBL] [Abstract][Full Text] [Related]
14. [Antimycobacterial activity of a newly synthesized fluoroquinolone, Y-26611]. Tomioka H; Sato K; Saito H; Ikeda Y Kekkaku; 1992 Jul; 67(7):515-20. PubMed ID: 1331603 [TBL] [Abstract][Full Text] [Related]
15. [In vitro antimicrobial activities of quinolones, rifamycins and macrolides against Mycobacterium tuberculosis and M.avium complex: attempt to establish new assay methods which accurately reflect therapeutic effects of test agents in vivo]. Sato K; Tomioka H Kekkaku; 1999 Jan; 74(1):63-70. PubMed ID: 10067057 [TBL] [Abstract][Full Text] [Related]
16. [Chemotherapy of pulmonary Mycobacterium kansasii infection]. Mizutani S Kekkaku; 1996 Sep; 71(9):527-31. PubMed ID: 8914388 [TBL] [Abstract][Full Text] [Related]
17. Therapeutic effect of KRM-1648 with various antimicrobials against Mycobacterium avium complex infection in mice. Saito H; Tomioka H; Sato K; Kawahara S; Hidaka T; Dekio S Tuber Lung Dis; 1995 Feb; 76(1):51-8. PubMed ID: 7718848 [TBL] [Abstract][Full Text] [Related]
18. [MICs and MBCs of levofloxacin, clarithromycin, and KRM-1648 for Mycobacterium tuberculosis and M. avium complex residing in MONO-MAC-6 human macrophage-like cell and A-549 human type II alveolar epithelial cell lines]. Sato K; Ogasawara K; Akaki T; Tomioka H Kekkaku; 1999 Jul; 74(7):571-7. PubMed ID: 10481412 [TBL] [Abstract][Full Text] [Related]
19. In vitro and in vivo activities of clarithromycin against the Mycobacterium avium complex. Hajime Saito ; Haruaki Tomioka ; Katsumasa Sato ; Satoshi Dekio Int J Antimicrob Agents; 1994 Aug; 4(3):175-81. PubMed ID: 18611608 [TBL] [Abstract][Full Text] [Related]
20. [In vitro and in vivo activities of chemically synthesized lipid A-subunit analogue, JTP3309, against mycobacterial infections in mice and in mouse peritoneal macrophages]. Suzuki H; Saito H; Sato K; Tomioka H Kekkaku; 1995 Apr; 70(4):285-92. PubMed ID: 7760537 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]